Your browser doesn't support javascript.
loading
Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".
Feldmann, Anja; Arndt, Claudia; Bergmann, Ralf; Loff, Simon; Cartellieri, Marc; Bachmann, Dominik; Aliperta, Roberta; Hetzenecker, Mirjam; Ludwig, Florian; Albert, Susann; Ziller-Walter, Pauline; Kegler, Alexandra; Koristka, Stefanie; Gärtner, Sebastian; Schmitz, Marc; Ehninger, Armin; Ehninger, Gerhard; Pietzsch, Jens; Steinbach, Jörg; Bachmann, Michael.
Afiliación
  • Feldmann A; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
  • Arndt C; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
  • Bergmann R; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
  • Loff S; UniversityCancerCenter (UCC) 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany.
  • Cartellieri M; GEMoaB Monoclonals GmbH, Dresden, Germany.
  • Bachmann D; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
  • Aliperta R; Cellex Patient Treatment GmbH, Dresden, Germany.
  • Hetzenecker M; UniversityCancerCenter (UCC) 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany.
  • Ludwig F; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
  • Albert S; UniversityCancerCenter (UCC) 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany.
  • Ziller-Walter P; UniversityCancerCenter (UCC) 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany.
  • Kegler A; UniversityCancerCenter (UCC) 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany.
  • Koristka S; UniversityCancerCenter (UCC) 'Carl Gustav Carus' TU Dresden, Tumor Immunology, Dresden, Germany.
  • Gärtner S; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
  • Schmitz M; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
  • Ehninger A; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
  • Ehninger G; Institute of Immunology, 'Carl Gustav Carus', TU Dresden, Dresden, Germany.
  • Pietzsch J; German Cancer Consortium (DKTK), partner site Dresden; and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Steinbach J; National Center for Tumor Diseases (NCT), Dresden, 'Carl Gustav Carus' TU Dresden, Dresden, Germany.
  • Bachmann M; GEMoaB Monoclonals GmbH, Dresden, Germany.
Oncotarget ; 8(19): 31368-31385, 2017 May 09.
Article en En | MEDLINE | ID: mdl-28404896
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Proteínas Recombinantes de Fusión / Receptores de Antígenos de Linfocitos T / Linfocitos T / Antígenos de Neoplasias / Proteínas de Neoplasias Límite: Animals / Humans / Male Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Proteínas Recombinantes de Fusión / Receptores de Antígenos de Linfocitos T / Linfocitos T / Antígenos de Neoplasias / Proteínas de Neoplasias Límite: Animals / Humans / Male Idioma: En Revista: Oncotarget Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos